TVTX Market Analysis
Wall Street coverage
third-party contextWall Street coverage
$58.36median target· current $56.71 (+2.9%)15 analysts
Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
News & Sentiment
49 articles · sorted by datePage 1 of 3 · 49 total
Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
Fundamentals
Updated daily after market closeP/E ratio—Forward 77.52
EPS (TTM)$-0.500.0% YoY
Profit margin-4.0%HEALTHCARE
Market cap$5.27BMid cap
Valuation
- Forward P/E
- 77.52
- PEG ratio
- —
- P/B
- 53.41
- P/S (TTM)
- 9.84
- EV/EBITDA
- 138.46
Profitability & growth
- ROE (TTM)
- -69.4%
- Operating margin
- -29.0%
- Revenue growth YoY
- 55.6%
- Dividend yield
- —
- Beta
- 1.11
Last earnings
May 4, 2026 · Estimate $-0.30 · Reported $-0.40
Analyst estimate. Actual results often differ.
Ratios are point-in-time. Historical metrics — no guarantees about what comes next.
About Travere Therapeutics Inc
Company profileTravere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development and commercialization of therapies for the treatment of rare diseases. The company is headquartered in San Diego, California.
Classification
- Sector
- Healthcare
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Country
- USA
- Currency
- USD
Company profile
- HQ
- 3611 VALLEY CENTRE DRIVE, SAN DIEGO, CA
- Fiscal year end
- December
- Latest quarter
- Mar 31, 2026
Market cap$5.27B
Shares outstanding$93.0M
52W high$60.10
52W low$15.03
We're educators, not advisors. We don't make buy or sell recommendations under any circumstance. All content is for educational purposes. Past performance doesn't guarantee future results. Your decisions are your own. Disclaimer
Balanced Agent